STOCK TITAN
  1. Home
  2. Sec-filings
  3. LXRX
  4. [Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity

Lexicon (LXRX) CEO Exton exercises RSUs and withholds shares for taxes

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LEXICON PHARMACEUTICALS, INC. Chief Executive Officer Michael Exton reported equity award activity involving restricted stock units and common stock on February 28, 2026. He exercised or converted 503,263 restricted stock units, receiving an equivalent number of common shares at a stated price of $0.00 per share.

In a related tax-withholding disposition, 204,831 common shares were withheld by the company at $1.47 per share to satisfy withholding obligations. Following these transactions, Exton directly held 1,006,527 restricted stock units and 298,432 common shares. The footnotes clarify that each restricted stock unit converts into one share and that vesting occurs in three equal annual installments after grant.

Positive

  • None.

Negative

  • None.
Insider Exton Michael
Role Chief Executive Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 503,263 $0.00 --
Exercise Common Stock 503,263 $0.00 --
Tax Withholding Common Stock 204,831 $1.47 $301K
Holdings After Transaction: Restricted Stock Units — 1,006,527 shares (Direct); Common Stock — 503,263 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of common stock. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Exton Michael
(Last) (First) (Middle)
2445 TECHNOLOGY FOREST BLVD
11TH FLOOR
(Street)
THE WOODLANDS TX 77381
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/28/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/28/2026 M 503,263 A (1) 503,263 D
Common Stock 02/28/2026 F(2) 204,831 D $1.47 298,432 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/28/2026 M 503,263 (3) (3) Common Stock 503,263 (1) 1,006,527 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
3. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
/s/ Michael Exton, Ph.D. 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did LXRX CEO Michael Exton report on this Form 4?

Michael Exton reported exercising 503,263 restricted stock units into common stock at $0.00 per share and a related tax-withholding disposition of 204,831 common shares at $1.47 per share. These moves reflect equity award vesting and associated tax settlement rather than open-market buying or selling.

How many Lexicon Pharmaceuticals (LXRX) shares did the CEO acquire and dispose in this filing?

The CEO acquired 503,263 shares of common stock through the exercise or conversion of restricted stock units and disposed of 204,831 shares through a tax-withholding transaction. The net effect is an increase in directly held common shares, with the disposition solely to cover tax obligations.

What are the vesting terms of Michael Exton’s restricted stock units at Lexicon (LXRX)?

The restricted stock units vest in three equal installments, with one-third of the shares vesting on February 28 of each of the three years following the year of grant. Each vested restricted stock unit converts into one share of Lexicon Pharmaceuticals common stock upon settlement.

How many Lexicon (LXRX) securities does the CEO hold after the reported transactions?

After these transactions, Michael Exton directly holds 1,006,527 restricted stock units and 298,432 shares of common stock. These figures reflect the completed RSU exercise, issuance of common shares, and the withholding of 204,831 shares to satisfy his related tax obligations.

Was the 204,831-share disposition in LXRX stock an open-market sale by the CEO?

No, the 204,831-share disposition was not an open-market sale. It represents shares withheld by the company at $1.47 per share to satisfy Michael Exton’s tax withholding obligations related to his restricted stock unit exercise and resulting common stock issuance.